Your session is about to expire
← Back to Search
Group Lifestyle Balance for Stroke (GLB-CVA Trial)
N/A
Waitlist Available
Led By Simon J Driver, PhD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3, 6, 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether the Group Lifestyle Balance program can help people with stroke lose weight and improve other health outcomes.
Who is the study for?
This trial is for individuals aged 18-85 who have had any type of stroke at least a year ago, with a BMI of 25 or higher. They must be able to understand English and not live in a hospital or similar facility. Pregnant individuals, those with eating disorders, low cognition, or conditions that make physical activity unsafe are excluded.
What is being tested?
The study tests the Group Lifestyle Balance (GLB) program tailored for stroke survivors against usual care practices. It measures the effectiveness on weight management and other health outcomes after 3, 6, and 12 months from starting the program.
What are the potential side effects?
Since this trial involves lifestyle changes rather than medication, side effects may include muscle soreness or fatigue due to increased physical activity. Emotional distress could also occur as participants adjust to new diet and exercise routines.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 3, 6, 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3, 6, 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in weight
Secondary study objectives
10 Meter Walk Test (10MWT)
6 Minute Walk Test (6MWT)
Arm Circumference
+26 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Wait-List ControlExperimental Treatment1 Intervention
The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
Group II: GLB Weight-Loss InterventionExperimental Treatment1 Intervention
The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Group Lifestyle Balance
2015
N/A
~130
Find a Location
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor
206 Previous Clinical Trials
203,360 Total Patients Enrolled
7 Trials studying Stroke
338 Patients Enrolled for Stroke
National Institute on Disability, Independent Living, and Rehabilitation ResearchFED
80 Previous Clinical Trials
10,082 Total Patients Enrolled
7 Trials studying Stroke
2,366 Patients Enrolled for Stroke
Simon J Driver, PhDPrincipal InvestigatorBaylor Scott & White Institute for Rehabilitation (BSWIR)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with an eating disorder before.You are between 18 and 85 years old.You are currently taking medicine for type 2 diabetes.You had a stroke at least 12 months ago.You have had any type of stroke.You have a body mass index (BMI) of 25 or higher.Having trouble with memory or thinking clearly.Medical conditions that make it unsafe for you to be physically active.
Research Study Groups:
This trial has the following groups:- Group 1: Wait-List Control
- Group 2: GLB Weight-Loss Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.